Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway
Open Access
- 16 May 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 2 (3) , oeac036
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but highly morbid complication after adenoviral vector-based SARS-CoV-2 vaccination. The pre-VITT syndrome is defined as vaccine-induced immune thrombocytopenia without thrombosis typically presenting with new-onset headache. This review aims to identify at-risk patients before complications such as cerebral venous sinus thrombosis occur. We review previously published reports of 19 patients (median age 35 years, range 23–74; 16 females) who met the diagnostic criteria for a pre-VITT syndrome. Seven patients progressed to VITT, 12 patients did not. Patients who experienced VITT received delayed treatment. The median interval between the onset of headache and VITT-treatment (i.e. anticoagulation, immune globulins, or corticosteroids) was 5 days (range 1–8 days) compared with 2 days (0–5 days) in those without subsequent VITT (P = 0.033). The interval from onset of headache to anticoagulation was longer in patients with VITT (median 7 vs. 2 days; range 3–9 vs. 0–7 days; P = 0.01). Anticoagulation was safe in all patients with a pre-VITT syndrome as no haemorrhagic complications occurred after anticoagulation was started despite low platelets. The transient decline of platelet count after admission was significantly more pronounced in patients who progressed to VITT (median 67 vs. 0 × 103/µL; range 0–77 × 103/µL vs. 0–10 × 103/µL; P = 0.005). d-dimers did not differ between groups. Pre-VITT syndrome is a ‘red flag’ and allows to identify and preemptively treat patients at-risk of further progression to VITT. However, it must be distinguished from post-vaccination immune thrombocytopenia.Keywords
This publication has 33 references indexed in Scilit:
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccinesThe American Journal of Emergency Medicine, 2021
- AZD1222 vaccine‐related coagulopathy and thrombocytopenia without thrombosis in a young femaleBritish Journal of Haematology, 2021
- Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT)Journal of Thrombosis and Haemostasis, 2021
- The Performance of CT versus MRI in the Differential Diagnosis of Cerebral Venous ThrombosisThrombosis and Haemostasis, 2018
- Analysis of Body-wide Unfractionated Tissue Data to Identify a Core Human Endothelial TranscriptomeCell Systems, 2016
- Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?Immunologic Research, 2016
- Ischemic Limb Gangrene with PulsesNew England Journal of Medicine, 2015
- Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndromeBlood, 2015
- Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous ThrombosisAnnals of Internal Medicine, 2001